Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ : CRBP)

( )
CRBP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.09%345.740.0%$4309.25m
BNTXBioNTech SE -0.86%292.390.0%$812.11m
NVAXNovavax, Inc. -0.27%134.9979.4%$758.79m
AMGNAmgen, Inc. 0.51%208.681.4%$526.19m
REGNRegeneron Pharmaceuticals, Inc. 2.77%592.152.7%$478.99m
SNSSSunesis Pharmaceuticals, Inc. -0.80%6.210.7%$434.10m
GILDGilead Sciences, Inc. 0.09%67.731.0%$397.88m
CCXIChemoCentryx, Inc. -3.57%33.722.9%$386.50m
ILMNIllumina, Inc. -0.85%417.193.3%$357.19m
XLRNAcceleron Pharma, Inc. 0.00%173.785.3%$335.39m
OCGNOcugen, Inc. -2.03%9.150.0%$303.34m
VRTXVertex Pharmaceuticals, Inc. -0.50%184.071.9%$274.05m
BIIBBiogen, Inc. 0.44%271.121.8%$271.81m
XENEXenon Pharmaceuticals, Inc. -0.52%30.570.4%$164.85m
CRSPCRISPR Therapeutics AG -1.70%95.060.6%$159.07m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.